Compare NCNA & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCNA | JAGX |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 4.9M |
| IPO Year | 2017 | 2014 |
| Metric | NCNA | JAGX |
|---|---|---|
| Price | $1.48 | $0.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 36.3K | ★ 86.7K |
| Earning Date | 06-01-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,511,000.00 |
| Revenue This Year | N/A | $61.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.21 | $0.22 |
| 52 Week High | $7.01 | $8.00 |
| Indicator | NCNA | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 46.95 | 26.44 |
| Support Level | $1.33 | $0.60 |
| Resistance Level | $1.41 | $0.99 |
| Average True Range (ATR) | 0.07 | 0.12 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 76.18 | 6.54 |
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.